Drug intelligence / Profile preview

CXX218

Development stage: Preclinical
Lead developer: Chance Pharmaceuticals
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Inhalation

Overview

CXX218 is a preclinical-stage, dual-target nanobody being developed by Chanceon Pharmaceuticals for the treatment of asthma. It is formulated as an inhaled dry powder using spray-drying technology. While the specific molecular targets for CXX218 are currently undisclosed by the developer, the drug belongs to a pipeline of innovative nanobody-based inhaled therapies designed to provide targeted delivery to the lungs, potentially offering improved efficacy and safety over systemic biologics for respiratory diseases.

Beyond the preview

Go deeper on CXX218.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CXX218.

Explore the full profile